GLP-1 Peptide
Glucagon Like Peptide (GLP-1) is widely viewed as an important emerging treatment for diabetes and obesity. CellMed is working with GLP-1 in two different ways.
First, CellMed is using the GLP-1 protein as the active ingredient in the CellBeads Neuro programme.
Second, CellMed has discovered a novel GLP-1 drug which is part of a new family of GLP-1 analogues.
Intellectual property protecting these new peptides is now in place and CellMed's preclinical data in this field are promising. The Company is now in preliminary discussions with potential licensing partners who are active in the field of diabetes.